4/26/2007

The FDA lacks authority to force participants at hearings to reveal ties they have to drugmakers, so some end up advocating drugs of firms that donated to them. One case involved the Cancer Research and Prevention Foundation telling an advisory panel the group had no ties to OSI Pharmaceuticals, whose Tarceva drug for treating pancreatic cancer was being reviewed. OSI actually had been contributing funds to the foundation for at least two years when the representative testified.

Related Summaries